IP Library Granted Patent US 9,399,760
Granted Patent B2
US 9,399,760 · App. 13/967,410 · Granted Jul 26, 2016

Molecular marker for cancer stem cell

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,399,760
App. No.
13/967,410
Granted
Jul 26, 2016
Kind
B2
Abstract

A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.

Claims (5)

1. A method for treating a DNAJB8 expressing tumor comprising a step of administering an isolated peptide as an active ingredient, wherein the isolated peptide

(i) consists of AFMEAFSSF (SEQ ID NO: 71), or

(ii) consists of AFMEAFSSF (SEQ ID NO: 71) in which the second amino acid from N-terminal is substituted to tyrosine, tryptophan, phenylalanine or methionine and/or the C-terminal amino acid is substituted to leucine, isoleucine, tryptophan, phenylalanine or methionine; and

wherein the isolated peptide has HLA-A24 binding ability.

2. A method according to claim 1 , wherein the isolated peptide consists of AFMEAFSSF (SEQ ID NO: 71).

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2024
From: SUMITOMO PHARMA CO., LTD.
To: SAPPORO MEDICAL UNIVERSITY
Reel/Frame 069340/0905 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2024
From: SAPPORO MEDICAL UNIVERSITY
To: ASSOCIATION FOR KOKICHI KIKUCHI MEMORIAL ACADEMIC PROMOTION
Reel/Frame 069340/0933 →
CHANGE OF NAME Recorded Nov 21, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 061972/0730 →
CHANGE OF NAME Recorded Feb 5, 2015
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 034921/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2013
From: TORIGOE, TOSHIHIKO; HIROHASHI, YOSHIHIKO; SATOH, NORIYUKI; KAMIGUCHI, KENJIRO; MORITA, RENA; NISHIZAWA, SATOSHI; TAKAHASHI, AKARI
To: DAINIPPON SUMITOMO PHARMA CO., LTD.; SAPPORO MEDICAL UNIVERSITY
Reel/Frame 031516/0010 →